Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of therapy for the management of acute pain. Cyclooxygenase (COX) enzyme is of particular interest because it is the major target of NSAIDs. Although NSAIDs are remarkably effective in the management of pain and inflammation, their use is limited by several adverse effects including gastrointestinal bleeding and ulceration, impaired renal function, and inhibition of platelet aggregation. Discovery of a second cyclooxygenase, COX-2, led to the hypothesis that NSAID side effects could be decreased, as the inhibition of COX-2 is more directly implicated in ameliorating inflammation while the inhibition of COX-1 is related to adverse effects in the GI tract. This stimulated the development of selective COX-2 inhibitors (coxibs) that are better tolerated than nonselective NSAIDs but comparable in analgesic efficacy. This article provides an overview on the therapeutic use of selective COX-2 inhibitors for relief of acute pain, largely based on clinical trials in patients undergoing the surgical removal of impacted third molars, with focus on analgesic efficacy and the potential safety associated with their use compared to dual COX-1/COX-2 inhibitors.
Keywords: cyclooxygenase-1, cyclooxygenase-2, non-steroidal anti-inflammatory drugs, selective cyclooxygenase inhibitors, prostaglandins, acute pain, oral surgery model
Current Pharmaceutical Design
Title: The Role of COX-2 in Acute Pain and the Use of Selective COX-2 Inhibitors for Acute Pain Relief
Volume: 11 Issue: 14
Author(s): Y. Lee, C. Rodriguez and R. A. Dionne
Affiliation:
Keywords: cyclooxygenase-1, cyclooxygenase-2, non-steroidal anti-inflammatory drugs, selective cyclooxygenase inhibitors, prostaglandins, acute pain, oral surgery model
Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of therapy for the management of acute pain. Cyclooxygenase (COX) enzyme is of particular interest because it is the major target of NSAIDs. Although NSAIDs are remarkably effective in the management of pain and inflammation, their use is limited by several adverse effects including gastrointestinal bleeding and ulceration, impaired renal function, and inhibition of platelet aggregation. Discovery of a second cyclooxygenase, COX-2, led to the hypothesis that NSAID side effects could be decreased, as the inhibition of COX-2 is more directly implicated in ameliorating inflammation while the inhibition of COX-1 is related to adverse effects in the GI tract. This stimulated the development of selective COX-2 inhibitors (coxibs) that are better tolerated than nonselective NSAIDs but comparable in analgesic efficacy. This article provides an overview on the therapeutic use of selective COX-2 inhibitors for relief of acute pain, largely based on clinical trials in patients undergoing the surgical removal of impacted third molars, with focus on analgesic efficacy and the potential safety associated with their use compared to dual COX-1/COX-2 inhibitors.
Export Options
About this article
Cite this article as:
Lee Y., Rodriguez C. and Dionne A. R., The Role of COX-2 in Acute Pain and the Use of Selective COX-2 Inhibitors for Acute Pain Relief, Current Pharmaceutical Design 2005; 11 (14) . https://dx.doi.org/10.2174/1381612053764896
DOI https://dx.doi.org/10.2174/1381612053764896 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Direct Cardiac Reprogramming with Engineered miRNA Scaffolds
Current Pharmaceutical Design NPY and Cardiac Diseases
Current Topics in Medicinal Chemistry BMP-9 Induced Osteogenic Differentiation of Mesenchymal Stem Cells: Molecular Mechanism and Therapeutic Potential
Current Gene Therapy Carotid Artery Stenting for the Prevention of Thromboembolic Stroke
Vascular Disease Prevention (Discontinued) Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry Cardiac Chamber Volumetric Assessment Using 3D Ultrasound - A Review
Current Pharmaceutical Design The Role of Radiopharmaceuticals in Amiodarone-Induced Thyroid Pathology
Current Radiopharmaceuticals Editorial: Thematic Issue-Topic–Diabetic Cardiovascular Disease–An Unmet Medical Need: Emerging Targets and Therapies-Introduction to the Special Issue
Cardiovascular & Hematological Agents in Medicinal Chemistry The Resurgence of Aldosterone in Hypertension and Cardiovascular Disease
Current Hypertension Reviews The Role of Mitochondria in Piperine Mediated Cardioprotection in Isoproterenol Induced Myocardial Ischemia
Current Pharmaceutical Design Contrast Agents in X-Ray Computed Tomography and Its Applications in Oncology
Anti-Cancer Agents in Medicinal Chemistry Diselenides and Selenocyanates as Versatile Precursors for the Synthesis of Pharmaceutically Relevant Compounds
Current Organic Synthesis Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design Role of Nuclear Imaging in Cardiac Amyloidosis Management: Clinical Evidence and Review of Literature
Current Medical Imaging The Impact of Dietary Habits and Nutritional Deficiencies in Urban African Patients Living with Heart Failure in Soweto, South Africa – A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Myocardial Energy Transport and Heart Failure
Current Cardiology Reviews Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology Gender Disparity in Lipid Target Achievements in High and Very High Atherosclerotic Cardiovascular Disease Risk Patients in the Arabian Gulf
Current Vascular Pharmacology Recent Patents and Advances in Hepatocyte-Like Cells Differentiation by Perinatal Stem Cells
Recent Patents on Regenerative Medicine Surgical Complications of Hyperglycaemia
Current Diabetes Reviews